Medical Developments International (FRA:M5D) EPS (Basic): €-0.00 (TTM As of Dec. 2025)


FRA:M5D Medical Developments International Ltd FRA:M5D
32 GF Score
Price €0.20
GF Value €0.35
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International EPS (Basic)?

Medical Developments International FRA:M5D +1.55% 32 EPS (Basic) is €-0.00 as of Dec. 2025. GuruFocus rates FRA:M5D with a GF Score™ of 32/100 and a GF Value™ of €0.35 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Medical Developments International's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.00.

Medical Developments International's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.00.

Medical Developments International's EPS without NRI for the six months ended in Dec. 2025 was €-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Medical Developments International's highest 3-Year average EPS without NRI Growth Rate was 71.00% per year. The lowest was -67.40% per year. And the median was -7.20% per year.

Medical Developments International  (FRA:M5D) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Medical Developments International EPS (Basic) Related Terms

Medical Developments International EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Medical Developments International's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International EPS (Basic) Chart

Medical Developments International Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.11 -0.04 -0.29 0.00

Medical Developments International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.21 0.00 -0.00 -0.00
FRA:M5D
32GF Score
Medical Developments International Ltd FRA:M5D
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medical Developments International EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Medical Developments International's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0.053-0)/109.992
=0.00

Medical Developments International's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.128-0)/112.658
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.00 mean?
Medical Developments International (FRA:M5D) has a EPS (Basic) of €-0.00 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Medical Developments International and its competitors.
Is Medical Developments International's EPS (Basic) too high?
Medical Developments International's current EPS (Basic) is €-0.00. Overall, Medical Developments International has a GF Score™ of 32/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's EPS (Basic) compare to ZTS?
Medical Developments International's EPS (Basic) of €-0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Medical Developments International and its competitors. Medical Developments International's current EPS (Basic) is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (FRA:M5D) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.35, compared to a current price of €0.20 — trading 43.7% below its estimated fair value. The current EPS (Basic) is €-0.00. Medical Developments International's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current EPS (Basic) is €-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (FRA:M5D) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of €0.20 is trading 43.7% below its estimated GF Value™ of €0.35. GuruFocus considers Medical Developments International to be Significantly Undervalued.

Key valuation signals for FRA:M5D:

  • EPS (Basic): €-0.00
  • GF Value™: €0.35 vs. price of €0.20 (43.7% below fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Developments International Business Description

Other Exchanges MDDVF:USAMVP:Australia
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
32GF Score

Get the complete analysis for FRA:M5D

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.35
GF Value